RJA
GILD icon

Raymond James & Associates’s Gilead Sciences GILD Stock Holding History

Raymond James & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,000
Closed -$7K – 3622
2020
Q2 		$7K Buy
+25,000
New +$1.92M ﹤0.01% 3491

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Raymond James & Associates's GILD Position: Q3 2024 in Review

Raymond James & Associates increased its Gilead Sciences (GILD) stake by 4.7% in Q3 2024, buying an estimated $8.32M and bringing the position to 2,411,768 shares worth $202M. The position accounts for 0.12% of the portfolio, ranked #146.

Raymond James & Associates first reported a position in GILD in Q2 2013 and has held it in 46 quarters since. The position peaked at $243M in Q4 2022. 1,719 funds tracked by Wall St. Rank hold GILD as of Q3 2024.

  • Raymond James & Associates held 2,411,768 shares of Gilead Sciences worth $202M as of Q3 2024.
  • Raymond James & Associates bought 109,014 Gilead Sciences shares in Q3 2024, an estimated $8.32M.
  • Gilead Sciences made up 0.12% of Raymond James & Associates's portfolio in Q3 2024, its #146 holding.
  • Raymond James & Associates first reported a position in Gilead Sciences in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Gilead Sciences position peaked at $243M in Q4 2022.
  • 1,719 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.